PMC:4822111 / 5062-5407 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4822111","sourcedb":"PMC","sourceid":"4822111","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4822111","text":"Eribulin phase II trials\nThe efficacy and safety of eribulin (1.4 mg/m2 on day 1 and day 8 of a 21-day cycle) have been evaluated in three phase II studies in patients with LABC or mBC pretreated with an anthracycline and a taxane (Table 2) [181920]. In these studies, eribulin demonstrated antitumor activity with a manageable toxicity profile.","divisions":[{"label":"Title","span":{"begin":0,"end":24}}],"tracks":[{"project":"2_test","denotations":[{"id":"27066091-20679609-56335776","span":{"begin":242,"end":244},"obj":"20679609"},{"id":"27066091-19349550-56335777","span":{"begin":242,"end":246},"obj":"19349550"},{"id":"27066091-21989327-56335778","span":{"begin":242,"end":248},"obj":"21989327"}],"attributes":[{"subj":"27066091-20679609-56335776","pred":"source","obj":"2_test"},{"subj":"27066091-19349550-56335777","pred":"source","obj":"2_test"},{"subj":"27066091-21989327-56335778","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93ecea","default":true}]}]}}